연구성과로 돌아가기

2021 연구성과별 연구자 정보 (742 / 2991)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Doerffel, Yvonne Doerffel, Y 13 Charite, Berlin, Germany ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Forman, Lisa Forman, L 14 Univ Colorado, Aurora, CO USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Freilich, Bradley Freilich, B 15 Kansas City Res Inst, Kansas City, KS USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Gheorghe, Liana Gheorghe, L 16 Fundeni Clin Inst, Bucharest, Romania ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Gonzalez, Maria Sarai González, MS 17 Consultorio Doctora Maria Sarai Gonzalez Huezo, Metepec, Mexico ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Harrison, Stephen Harrison, S 18 Pinnacle Clin Res, San Antonio, TX USA GON-3283-2022 Harrison, Stephen ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Huang, Jonathan Huang, J 19 Univ Rochester, Rochester, NY 14627 USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Jeong, Sook-Hyang Jeong, SH 20 Seoul Natl Univ, Bundang Hosp, Seongnam Si, South Korea J-5642-2012 Jeong, Sook-Hyang ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Kim, Seung Up Kim, SU 21 Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea L-4239-2013 Kim, Sun ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Lake, John Lake, J 22 Univ Minnesota, Minneapolis, MN USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Odin, Joseph Odin, J 23 Mt Sinai Hosp, New York, NY 10029 USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Tak, Won Young Tak, WY 24 Kyungpook Natl Univ Hosp, Daegu, South Korea ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Tobias, Hillel Tobias, H 25 Concorde Med Grp, New York, NY USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Vierling, John M. Vierling, JM 26 Baylor Coll Med, Houston, TX 77030 USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Yang, Ke Yang, K 27 CymaBay Therapeut, Newark, CA USA ychoi@cymabay.com;
페이지 이동: